ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 704

Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort

Ruba Kado1, Emily Siegwald2, Emily Lewis2, Mitch Goodsitt3, Emmanuel Christodoulou3, Ella Kazerooni3 and W. Joseph McCune4, 1Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Michigan, Ann Arbor, MI, 3Radiology, University of Michigan, Ann Arbor, MI, 4Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lupus, pulmonary complications and radiology

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Ionizing radiation from CT scanning can increase cancer risk.  Lupus patients are frequently evaluated for chest pain and may have multiple pulmonary embolism CT (PE-CT) scans in addition to other exposures to diagnostic or therapeutic radiation.

The objective of this study is twofold i) Determine the incidence of PE in University of Michigan Lupus Cohort patients who have undergone PE -CT scans ii) Estimate associated breast and lung cancer incidence

Methods: We reviewed records of patients in the Michigan Lupus Cohort (N=856), and for each patient determined the number and outcome of PE-CT scans. All patients gave informed consent for review of their records. Based on estimated x-ray exposure from a state of the art GE Discovery CT750 HD CT scanner for an arterial chest scan, we estimated radiation dosage to the breast and lung in an average sized adult woman, utilizing CT-Expo software package.{1]   We used the dose information and the patient’s age at the time of the CT scan and tabulated risks according to the BEIR VII report to estimate the increased lifetime incidence risks of breast and lung cancer.   Risks from multiple CT scans were summed.

Results: 183/856 (21%) patients underwent a total of 358 PE CT scans. The overall rate of positivity was 7.5%. The likelihood of a positive scan decreased in proportion to the number of scans that had been previously performed. (Figure 1) For patients undergoing their first through third CT scans the rate of positivity for PE was 9.2 %, whereas patients undergoing their fourth through tenth CT scans had 1.6% positivity.

We estimated radiation doses of to the breast and lung in female patients from a PE CT arterial scan, as 20mGy and 22mGy respectively. Separating patients based on age and number of CT scans, the estimated lifetime increase incidence risk of breast and lung cancer was calculated.  In this simplified model the range of added risk for breast and lung cancer respectively per 100,000 female patients was 0-100 in 72% and 72%; 100- 500 in 25% and 28% and 500- 1000 in 4% and 1%.

Image/graph:

Description: WR0

Conclusion: Patients with multiple previous PE CT scans had lower likelihood of a positive result on subsequent scans and higher risks of malignancy. Our conservative estimates of radiation exposure, that do not account for higher radiation doses from older CT scanners, indicate sufficient risk to warrant more precise characterization of radiation exposure in this population; and encourage development of guidelines for PE screening for patients with systemic lupus erythematosus and recurrent chest pain. The magnitude of risk should not discourage performance of PE CT when clinically indicated.

References: G. Stamm and H. D. Nagel, “CT-expo—A novel program for dose evaluation in CT,” RoFo: Fortschritte auf dem Gebiete der Ro¨ntgenstrahlen und der Nuklearmedizin 174, 1570–1576 (2002)

 


Disclosure:

R. Kado,
None;

E. Siegwald,
None;

E. Lewis,
None;

M. Goodsitt,
None;

E. Christodoulou,
None;

E. Kazerooni,
None;

W. J. McCune,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-and-associated-risk-of-pulmonary-embolism-ct-scans-in-the-michigan-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology